Publications depuis 2010

Articles

  • Pliquett J, Amor S, Ponce-Vargas M, Laly M, Racoeur C, Rousselin Y, Denat F, Bettaïeb A, Fleurat-Lessard P, Paul C, Goze C, Bodio E.  Design of a multifunctionalizable BODIPY platform for the facile elaboration of a large series of gold(I)-based optical theranostics. Dalton Transaction. 2018. DOI: 10.1039/C8DT02364F
  • Martin A, Seignez C, Racoeur C, Isambert N, Mabrouk N, Scagliarini A, Reveneau S, Arnould L, Bettaieb A, Jeannin JF, Catherine Paul. Tumor-derived granzyme B-expressing neutrophils acquire antitumor potential after lipid A treatment. Oncotarget,  2018 9(47):28364-28378.
  • Ben Bahria-Sediki I, Chebil M, Sampaio C, Martel-Frachet V, Cherif M, Zermani R, Rammeh S, Ben Ammar Gaaied A, Bettaieb A. Prognostic value of soluble death receptor ligands in patients with transitional cell carcinoma of bladder. Urol Int, 2018 100(4):476-484
  • Dosset M, Rivera Vargas T, Lagrange A, Boidot R, Végran F, Roussey A, Dondaine L, Paul C, Lauret Marie-Joseph E, Martin F, Ryffel B, Borg C, Adotévi O, Ghiringhelli F and Apetoh A. Immunogenic cell death induction by chemotherapy promotes adaptive immune resistance in colorectal cancer via activation of the PD1/PD-L1 pathway. Oncoimmunol, 2018 15;7(6):e1433981
  • Romagny S, Bouaouiche S, Lucchi G, Ducoroy P, Bertoldo JB, Terenzi H, Bettaieb A, Plenchette S. S-nitrosylation of cIAP1 switches cancer cell fate from TNFα/TNFR1-mediated cell survival to cell death. Cancer Res. 2018 78(8):1948-1957.
  • Chotard F, Dondaine L, Balan C, Bettaieb A, Paul C, Le Gendre P, Bodio E.  Highly antiproliferative neutral Ru(II)-arene phosphine complexes. New J Chem, in press.
  • Brahim S, Aroui S, Ali R, Jeannin JF, Kennani A, Bettaieb A. The combination of Bleomycin with TRAIL agonists or PKC inhibitors sensitizes solid tumor cells to BLM-mediated apoptosis: new strategies to overcome chemotherapy resistance of tumors. Medicinal Chemistry Res 2017 26(9): 2105-2111.
  • Trommenschlager A, Bertrand B, Chotard F, Chalumeau-Delamasure S, Dondaine L, Picquet M, Denat F, Bettaieb A, Le Gendre P, Dutartre P, Paul C, Goze C and Bodio E. Gold(I)-BODIPY-imidazole bimetallic complexes as new potential anti-inflammatory and anticancer trackable agents. Dalton Transactions 2017 46(25):8051-8056.
  • Dondaine L, Escudero D, Ali M, Richard P, Denat F, Bettaieb A, Le Gendre P, Paul C, Jacquemin D, Goze C and Bodio E. Coumarin-phosphine-based smart probes for tracking biological relevant metal complexes: from theoretical to biological investigations. EurJIC. 2016 4: 545-553
  • Ben Bahria-Sediki I,·Yousfi N, Paul C, Chebil M, Cherif M, Zermani R, El Gaaied M,· Bettaieb A. Clinical significance of T-bet, GATA-3, and Bcl-6 transcription factor expression in bladder carcinoma. J Transl Med. 2016 14(1):144
  • Berthenet K, Boudesco C, Collura A, Svrcek M, Richaud S, Hammann A, Causse S, Yousfi N, Wandherwrick K, Duplomb L, Duval A, Garrido C, Jego G. Extracellular HSP110 skews macrophage polarization in colorectal cancer. Oncoimmunology. 2016 5(7):e1170264.
  • Burgy O, Wettstein G, Bellaye PS, Decologne N, Racoeur C, Goirand F, Beltramo G, Hernandez JF, Kenani A, Camus P, Bettaieb A, Garrido C, Bonniaud P. Deglycosylated bleomycin has the antitumor activity of bleomycin without pulmonary toxicity. Sci Transl Med. 2016 8(326):326ra20.
  • Ben Bahria-Sediki I, Sampaio C, Chebil M, Cherif M, Zermani R, Rammeh S, Ben Ammar El Gaaied A, Bettaieb A. Akt activation correlates with the tumor aggressiveness in Tunisian patients with bladder cancer. Tumour Biol. 2016 37(6):7873-9.
  • Lamrani M, Sassi N, Paul C, Yousfi N, Boucher B, Gauthier N, Labbé J, Seignez C, Racoeur C, Athias A,Guerreiro R, Vergely C, Rochette L, Bettaieb A, Jeannin JF. 2015. TLR4/IFNγ pathways induce tumor regression via NOS II-dependent NO and ROS production in murine breast cancer models. OncoImmunology. 5(5):e1123369.
  • Bentrari F, Chantôme A, Knights A, Jeannin, JF, Pance A. Oct-2 forms a complex with Oct-1 on the iNOS promoter and represses transcription by interfering with recruitment of RNA PolII by Oct-1. Nucleic Acids Research. 2015 43(20):9757-65.
  • Ali M, Dondaine L, Adolle A, Sampaio C, Chotard F, Richard P, Denat F, Bettaieb A, Le Gendre P, Laurens V, Goze C, Paul C*, Bodio E*. Anticancer agents: does a phosphonium behave like a gold(I) phosphine complex? Let a "smart" probe answer! J Med Chem. 2015 58(11):4521-8. Co-corresponding authors
  • Yousfi N, Pruvot B, Lopez T, Magadoux L, Franche N, Pichon L, Salvadori F, Solary E, Garrido C, Laurens V, Chluba J. The impact of tumor nitric oxide production on VEGFA expression and tumor growth in a zebrafish rat glioma xenograft model. PLoS One. 2015 10(3):e0120435.
  • Cortier M, Boina-Ali R, Racoeur C, Paul C, Solary E, Jeannin JF and Bettaieb A. H89 enhances the sensitivity of cancer cells to glyceryl trinitrate through a purinergic receptor-dependent pathway. Oncotarget 2015 6(9):6877-86.
  • Doulain PE, Decréau R, Racoeur C, Goncalves V, Dubrez L, Bettaieb A, Le Gendre P, Denat F, Paul C*, Goze C* and Bodio E*. Towards the elaboration of new gold-based optical theranostics. Dalton Transactions. 2015 44(11):4874-83.* co-corresponding authors
  • Tasan S, Licona C, Doulain PE, Michelin C, Gros C, Le GendreP, Harvey P, Paul C, Gaiddon C, Bodio E. Gold-phosphine porphyrin as potential metal-based theranostics. J. Biol. Inorg. Chem. 2015 20(1):143-54.
  • Seignez C, Martin A, Rollet CE, Racoeur C, Scagliarini A, Jeannin JF, Bettaieb A and Paul C. Senescence of tumor cells induced by oxaliplatin increases the efficiency of a lipid A immunotherapy via the recruitment of neutrophils. Oncotarget. 2014 5(22):11442-51.
  • Ali-Boina R, Cortier M, Decologne N, Racoeur-Godard C, Seignez C, Lamrani M, Jeannin JF, Paul C and Bettaieb A. Activation of Akt by the mammalian target of rapamycin complex 2 renders colon cancer cells sensitive to apoptosis induced by nitric oxide and akt inhibitor. Carcinogenesis & Mutagenesis. 2013 S8: 004
  • Marivin A, Berthelet J, Cartier J, Paul C, Gemble S, Morizot A, Boireau W, Saleh M, Bertoglio J, Solary E, Dubrez L. cIAP1 regulates TNF-mediated cdc42 activation and filopodia formation. Oncogene. 2013 33(48):5534-45.
  • Mirjolet C, Papa AL, Créhange G, Raguin O, Seignez C, Paul C, Truc G, Maingon P and Millot N. The radiosensitization effect of titanate nanotubes as a new tool in radiation therapy for glioblastoma: a proof-of-concept. Radiother Oncol. 2013 108(1):136-42.
  • Isambert N, Fumoleau P, Paul C, Ferrand C, Zanetta S, Bauer J, Ragot K, Lizard G, Jeannin JF, Bardou M. Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 13(1):172.
  • Reveneau S, Petrakis T, Goldring C, Chantôme A, Jeannin JF, and Pance A. Oct-1 cooperates with the TATA binding initiation complex to control rapid transcription of human iNOS. Cellular and Molecular Life Sciences. 2012 69:2609-2619.
  • Guery L, Benikhlef N, Gautier T, Paul C, Jego G, Dufour E, Jacquel A, Cally R, Manoury B, Vanden Berghe T, Vandenabeele P, Droin N and Solary E. Fine-tuning nucleophosmin in macrophage differentiation and activation. Blood 2011 118: 4694-704.
  • Cartier J, Berthelet J, Marivin A, Gemble S, Edmond V, Plenchette S, Lagrange B, Hammann A, Dupoux A, Delva L, Eymin B, Solary E, Dubrez L. Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription. Journal of Biology Chemistry. 2011 286:26406-26417.
  • Leon L, Subramaniam S, Cauvard O, Plenchette-Colas S, Paul C, Godard C, Martinez-Ruiz A, Legembre P, Jeannin JF and Bettaieb A. S-Nitrosylation of the Death Receptor Fas Promotes Fas Ligand-Mediated Apoptosis in Cancer Cells. Gastroenterology. 2011 140: 2009-18.
  • Gautier T *, Paul C *, Deckert V, Desrumaux C, Klein A, Labbé J, Le Guern N, Athias A., Monier S, Hammann A, Bettaieb A, Jeannin JF and Lagrost L. Innate immune response triggered by triacyl lipid A is dependent on phospholipid transfer protein (PLTP) gene expression. Faseb J. 2010 29: 3544-54 * Contributed equally to the present work.
  • Paul C *, Simon S*, Gibert B*, Virot S, Manero F and Arrigo AP. Dynamic processes that reflect anti-apoptotic strategies set up by HspB1 (Hsp27). Exp. Cell. Research. 2010 316:1535-1552 * Contributed equally to the present work.

Revues

  • Bettaieb A, Paul C, Plenchette S, Shan J, Chouchane L, Ghiringhelli F.  Precision Medicine in breast cancer: reality or utopia? Journal of Translational Medecine. 2017 15(1):139.
  • Bettaieb A, Paul C, Plenchette S. Exploration of Fas S-Nitrosylation by the Biotin Switch Assay.Methods Mol Biol. 2017. 1557:199-206.
  • Bouaouiche S, Dubrez L, Bettaieb A, Plenchette S. 2016. IAPs: Mediators of Oncogenesis and Targets for Anticancer Therapy. Crit Rev Oncog. 2016;21(5-6):399-411.
  • Plenchette S, Romagny S, Laurens V, Bettaieb A.NO et cancer : itinéraire d’un agent double. Médecine/Sciences. 2016 32(6):625-33.
  • Plenchette S, Romagny S, Laurens V, Bettaieb A. S-nitrosylation in TNF superfamily signaling pathway: implication in cancer. Redox Biology. 2015 6:507-15.
  • Magadoux L, Isambert N, Plenchette S, Jeannin JF, and Laurens V. Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer. International Journal of Oncology. 2014 45(3):919-28.
  • Garrido C, Paul C, Seigneuric R, Kampinga HH. The small heat shock proteins family: the long forgetten chaperones. Int. J. Biochem. Cell. Biol. 2012 44:1588-92.
  • Marivin A, Berthelet J, Plenchette S, Dubrez L.  The Inhibitor of Apoptosis (IAPs) in Adaptive Response to Cellular Stress. Cells. 2012 1(4):711-737.

Chapitres et livres

  • Jeannin JF. Lipid A in cancer therapies preclinical results. Adv Exp Med Biol. 2010. 667:1-3.
  • Reisser D and Jeannin JF. Lipid A-induced responses in vivo. Adv Exp Med Biol. 2010. 667:101-10.
  • Sassi , Paul C, Martin A, Bettaieb A and Jeannin JF. Treatment of cancer with lipid A. Adv Exp Med Biol. 2010. 667:69-80.
  • Jeannin JF. Conclusion Adv Exp Med Biol. 2010. 667:133-4.
  • Cortier M, Leon L, Sassi N, Paul C, Jeannin JF and Bettaieb A. NO is a promising enhancer for cancer therapy. 2010. Nitric Oxide and Cancer. Editor: Benjamin Bonavida.
  • Martin A, Seignez C, Paul C, Bettaieb A and Jeannin JF. Toll Like Receptor 2 and 4 in cancer immunotherapy, is Nitric Oxide mediator? Forum on Immunopathological Diseases and Therapeutics 2010. 1: 307-315.
  • Leon L, Lamrani M, Plenchette-Colas S, Jeannin JF, Bettaieb A. Post-translational regulation of Fas/CD95 in cell death and survival. Forum on immunopathological diseases and therapeutics. 2010. 297-305.
  • Bettaieb A, Plenchette S, Paul C, Laurens V, Romagny S and Jeannin JF.  S-nitrosylation of cancer cells. In Nitric Oxide and Cancer. Pathogenesis and Therapy (Editor: Benjamin Bonavida). 2015. p97-109.